Related Experiment Video
Updated: Jun 13, 2026

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
Published on: June 22, 2022
Cerebrolysin for acute ischaemic stroke
Lilia E Ziganshina1, Tatyana Abakumova, Alexandra Kuchaeva
1Department of Clinical Pharmacology and Pharmacotherapy, Kazan State Medical Academy, 11 Mushtari Street, 420012, 14-15 Malaya Krasnaya Street, 420015, Kazan, Tatarstan, Russian Federation.
Cerebrolysin showed no significant difference in death or adverse events for acute ischemic stroke patients in one trial. More large-scale studies are needed to evaluate its effectiveness on survival and dependency.
Area of Science:
- Neurology
- Pharmacology
Background:
- Cerebrolysin, a peptide mixture from porcine brain tissue, is used for acute ischemic stroke in Russia and China.
- It is proposed to have neuroprotective and neurotrophic properties.
Purpose of the Study:
- To evaluate the benefits and risks of cerebrolysin in acute ischemic stroke treatment.
Main Methods:
- Searched multiple databases (Cochrane, MEDLINE, EMBASE, etc.) up to February 2009.
- Included one randomized controlled trial comparing cerebrolysin to placebo in acute ischemic stroke patients.
Main Results:
- The single trial included 146 participants.
- No significant difference was found in mortality (RR 0.87, 95% CI 0.29 to 2.58) or adverse events (RR 1.62, 95% CI 0.69 to 3.82) between cerebrolysin and placebo groups.
Conclusions:
- Insufficient evidence exists to determine cerebrolysin's effect on survival and dependency in acute ischemic stroke.
- High-quality, large-scale randomized controlled trials are necessary to clarify its potential benefits.
More Related Videos
Related Concept Videos
Ischemic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology
Cerebral Edema ll: Pathophysiology
Transient Ischemic Attack l: Introduction

